Mode
Text Size
Log in / Sign up
N/A N=149 Prevention

VenaTech Convertible Vena Cava Filter U.S. Multi-Center Clinical Trial

Pulmonary Embolism

Enrolled (actual)
149
Serious AEs
42.3%
Results posted
Jul 2016
Primary outcome: Primary: Technical Success — 89 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
VenaTech Convertible Vena Cava Filter (Device); Vena Cava Filter Conversion (Procedure)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
B. Braun Interventional Systems, Inc
Primary completion
Sep 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Technical Success
89
SECONDARY
Major Device-Related Adverse Events in Converted Subjects

Summary

The investigation is designed to verify that clinical use of the vena cava filter does not raise new questions of safety or effectiveness compared to currently-marketed permanent filters.

Eligibility Criteria

Inclusion Criteria

  • The subject is 18 years of age or older
  • The subject is at a time-limited risk of pulmonary embolism as judged by the implanting or referring physician
  • In the physician's judgment, the subject requires prevention of pulmonary embolism and placement of a vena cava filter is indicated because anticoagulants are contraindicated, or the subject has experienced failure of anticoagulant therapy in thromboembolic diseases in the past, or the subject requires emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced
  • The subject, or their legal representative, is willing and able to provide informed consent
  • The subject is willing and able to comply with the requirements of the study protocol, including the predefined follow-up visit evaluations
  • The subject's vena cava diameter is ≤ 28 mm as evaluated by contrast venacavography and corrected for magnification

Exclusion Criteria

  • The subject is a female of childbearing potential and known to be, or suspected to be, pregnant (verified with a urine/blood pregnancy test), or unwilling to use an acceptable form of birth control for as long as the device is implanted
  • The subject is severely disabled and his/her life expectancy appears limited according to the investigator's opinion (≤ 6 months)
  • The subject already has an implanted vena cava filter
  • The subject has contrast allergy to both iodinated contrast and non-iodinated contrast materials
  • The subject has a duplicated IVC
  • The subject is bacteremic
  • The subject has an active malignancy with associated hypercoagulability or mortality likely preventing the VenaTech Convertible filter from being converted within 6 months of implant
  • The subject would be unavailable for follow-up
  • Filter implantation using the right internal jugular or femoral veins is not possible
  • There is no location available in the infrarenal inferior vena cava for placement of the VenaTech Convertible vena cava filter (assessed using contrast venacavography)
  • The subject is currently participating in another clinical study or has participated in one within the last 30 days or plans to participate in one during the next 6 months
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01112917). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search